CD8A and B-cell non-Hodgkin lymphoma: In preclinical studies, ALT-803 enhanced memory CD8+ T cell subpopulations and specific NK expansion, promoted the secretion of IFN-γ, and improved NK cell function in multiple animal models, including B cell lymphoma, glioblastoma, colon cancer, and ovarian cancer (60–62).